Klinická farmakologie a farmacie – 3/2020

www.klinickafarmakologie.cz  / KlinFarmakol Farm2020; 34(3): 108–115 / KLINICKÁ FARMAKOLOGIE A FARMACIE 115 ORIGINÁLNÍ PRÁCE Potrava jako důležitá součást maximalizace účinku a minimalizace rizik farmakoterapie – absorpce a gastrointestinální tolerance 31. Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord. Dec 2010; 11(4): 275–280. 32. Kendler DL, Ringe JD, Ste‑Marie LG, Vrijens B, Taylor EB, Delmas PD. Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int. Nov 2009; 20(11): 1895–902. 33. Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, OlofssonB. Influenceof foodonthebioavailabilityofanenteric­ ‑coated tablet formulation of omeprazole 20mg under re‑ peated dose conditions. Can J Gastroenterol. Nov‑Dec 1997; 11(8): 663–667. 34. Vaz‑da‑SilvaM, Loureiro AI, Nunes T, et al. Bioavailability and bioequivalence of two enteric‑coated formulations of ome‑ prazole in fasting and fed conditions. Clin Drug Investig. 2005; 25(6): 391–399. 35. Boltin D, Zvidi I, Raskin M, et al. Effect of Postprandial Ad‑ ministration of Esomeprazole on Reflux Symptoms in Gast‑ roesophageal Reflux Disease: A Randomized, Controlled Trial. Dig, DiS. 2018; 36(4): 257–263. 36. Hatlebakk JG, Katz PO, Camacho‑Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. Oct 2000; 14(10): 1267–72. 37. Gardner JD, Sloan S, Miner PB, Robinson M. Meal­ ‑stimulated gastric acid secretion and integrated gastric acidity in gastro‑oesophageal reflux disease. Aliment Phar‑ macol Ther. Apr 12003; 17(7): 945–953. 38. Puchalski TA, Krzyzanski W, Blum RA, Jusko WJ. Pharmaco‑ dynamic modeling of lansoprazole using an indirect irreversi‑ ble responsemodel. J Clin Pharmacol. Mar 2001; 41(3): 251–258. 39. Wilder‑Smith C, Rohss K, Bokelund Singh S, Sagar M, Nagy P. The effects of dose and timing of esomeprazole administra‑ tion on 24-h, daytime and night‑time acid inhibition in healthy volunteers.AlimentPharmacolTher.Nov2010;32(10):1249–1256. 40. Mussig S, Witzel L, Luhmann R, Schneider A. Morning and evening administration of pantoprazole: a study to compa‑ re the effect on 24-hour intragastric pH. Eur J Gastroenterol Hepatol. Jun 1997; 9(6): 599–602. 41. Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshi‑ ta Y. A comparative study of intragastric acidity during post­ ‑breakfast and pre‑dinner administration of low‑dose pro‑ ton pump inhibitors: a randomized three‑way crossover stu‑ dy. Aliment Pharmacol Ther. Nov 152006; 24(10): 1445–1451. 42. Skelin M, Lucijanic T, Amidzic Klaric D, et al. Factors Affec‑ ting Gastrointestinal Absorption of Levothyroxine: A Review. Clin Ther. Feb 2017; 39(2): 378–403. 43. Bach‑Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin con‑ centration.JClinEndocrinolMetab.Oct2009;94(10):3905–3912. 44. Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A. Effects of evening vs morning levothyroxine intake: a ran‑ domized double‑blind crossover trial. Arch Intern Med. Dec 132010; 170(22): 1996–2003. 45. Skelin M, Lucijanic T, Liberati‑Cizmek AM, et al. Effect of timing of levothyroxine administration on the treatment of hypothyroidism: a three‑period crossover randomized stu‑ dy. Endocrine. Nov 2018; 62(2): 432–439. 46. Srivastava S, Sharma G, Rathore M, et al. A Crossover Stu‑ dy Evaluating Effect of Timing of Levothyroxine on Thyroid Hormone Status in Patients of Hypothyroidism. J Assoc Phys‑ icians India. Sep 2018; 66(9): 37–40. 47. Giassi K, Piccoli V, da Costa Rodrigues T, Gorga Bandeira de Mello R. Evaluation of evening versus morning levothyroxi‑ ne intake in elderly (MONIALE). Trials. Dec 172019; 20(1): 742. 48. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glu‑ cose absorption in addition to increasing urinary glucose ex‑ cretion: results of a randomized, placebo‑controlled study. Diabetes Care. Aug 2013; 36(8): 2154–2161. 49. Ohgaki R, Wei L, Yamada K, et al. Interaction of the Sodium/ Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1andSGLT2.JPharmacolExpTher.Jul2016; 358(1):94–102. 50. MálekF. Inhibitoryangiotenzin‑konvertujícíhoenzymuvte‑ rapii kardiovaskulárních onemocnění – tradiční a nové indika‑ ce pro klinické použití lékové skupiny. Interní med. 2002; 4(8): 374–378. 51. White CM. Pharmacologic, pharmacokinetic, and thera‑ peutic differences among ACE inhibitors. Pharmacotherapy. May‑Jun 1998; 18(3): 588–99. 52. Špinar J, Vítovec J. Diagnostika a léčba hypertenzní krize. Interv Akut Kardiol 2006; 5: 78–79. 53. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. Jul 2013; 51(7): 549–561. 54. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Me‑ tab. Apr 2017; 19(4): 473–481. 55. DeFronzo RA, Goodman AM. Efficacy of metformin in pa‑ tients with non‑insulin‑dependent diabetes mellitus. The Mul‑ ticenter Metformin Study Group. N Engl J Med. Aug 311995; 333(9): 541–549. 56. Florez H, Luo J, Castillo‑Florez S, et al. Impact of metformin‑induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Post‑ grad Med. Mar 2010; 122(2): 112–120. 57. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gas‑ trointestinal tolerability of extended‑release metformin tab‑ lets compared to immediate‑release metformin tablets: re‑ sults of a retrospective cohort study. Curr Med Res Opin. Apr 2004; 20(4): 565–572. 58. Venerito M, Wex T, Malfertheiner P. Nonsteroidal Anti­ ‑Inflammatory Drug‑Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies. Pharmaceuticals (Basel). Jul 142010; 3(7): 2225–2237. 59. Wijma RA, Huttner A, Koch BCP, Mouton JW, Muller AE. Review of the pharmacokinetic properties of nitro‑ furantoin and nitroxoline. J Antimicrob Chemother 2018; 73: 2916–2926. 60. Beneš J. Antibiotika – systematika, vlastnosti, použití. Pra‑ ha: Grada Publishing, 2018.